%0 Journal Article
%A Liu, Anthony P Y
%A Smith, Kyle S
%A Kumar, Rahul
%A Paul, Leena
%A Bihannic, Laure
%A Lin, Tong
%A Maass, Kendra K
%A Pajtler, Kristian W
%A Chintagumpala, Murali
%A Su, Jack M
%A Bouffet, Eric
%A Fisher, Michael J
%A Gururangan, Sridharan
%A Cohn, Richard
%A Hassall, Tim
%A Hansford, Jordan R
%A Klimo, Paul
%A Boop, Frederick A
%A Stewart, Clinton F
%A Harreld, Julie H
%A Merchant, Thomas E
%A Tatevossian, Ruth G
%A Neale, Geoffrey
%A Lear, Matthew
%A Klco, Jeffery M
%A Orr, Brent A
%A Ellison, David W
%A Gilbertson, Richard J
%A Onar-Thomas, Arzu
%A Gajjar, Amar
%A Robinson, Giles W
%A Northcott, Paul A
%T Serial assessment of measurable residual disease in medulloblastoma liquid biopsies.
%J Cancer cell
%V 39
%N 11
%@ 1535-6108
%C New York, NY
%I Elsevier
%M DKFZ-2021-02340
%P 1519-1530.e4
%D 2021
%Z 2021 Nov 8;39(11):1519-1530.e4
%X Nearly one-third of children with medulloblastoma, a malignant embryonal tumor of the cerebellum, succumb to their disease. Conventional response monitoring by imaging and cerebrospinal fluid (CSF) cytology remains challenging, and a marker for measurable residual disease (MRD) is lacking. Here, we show the clinical utility of CSF-derived cell-free DNA (cfDNA) as a biomarker of MRD in serial samples collected from children with medulloblastoma (123 patients, 476 samples) enrolled on a prospective trial. Using low-coverage whole-genome sequencing, tumor-associated copy-number variations in CSF-derived cfDNA are investigated as an MRD surrogate. MRD is detected at baseline in 85
%K biomarkers (Other)
%K cell-free DNA (Other)
%K cerebrospinal fluid (Other)
%K childhood cancer (Other)
%K liquid biopsy (Other)
%K measurable residual disease (Other)
%K medulloblastoma (Other)
%K microscopic residual disease (Other)
%K minimal residual disease (Other)
%K relapse disease (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34678152
%R 10.1016/j.ccell.2021.09.012
%U https://inrepo02.dkfz.de/record/177206